Dendreon Corporation is seeking authorisation to open manufacturing sites at two new locations in the US for its prostate cancer vaccine, Provenge (sipuleucel-T), to meet demand for the treatment, David Urdal, CSO, told a London conference. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News
